AnnJi Pharmaceutical News
Dedicated to New Drug Development in Dermatology & Neurology
Press Release
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy’s Disease)
2024-05-16 – Topline results of the Phase 1b/2a clinical trial anticipated mid-year 2024 – Miami – May 16, 2024 – Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the completion of the last patient’s
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
2024-04-16 MIAMI, March 25, 2024 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that it will host a virtual key opinion leader (“KOL”) event highlighting expert perspectives on spinal bulbar muscular
Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy’s Disease)
2024-01-02 – Topline data remains on track for second quarter of 2024 – Miami, FL – January 2, 2024 – Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that all patients have been enrolled
AnnJi Invited to Meet with President Tsai as a Recipient of 2023 Bio Taiwan Awards
2023-12-11 President Tsai Ing-wen hosted the recipients of the “2023 Outstanding Company” Award at the Presidential Palace on December 8, 2023. Dr. Nick Li attended the reception on behalf of AnnJi Pharmaceutical Co. (AnnJi), the winner of the “Emerging Company of the Year “. AnnJi is an R&D based, clinical-stage new drug company dedicated to
Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy’s Disease)
Topline data expected in 2024 MIAMI, July 27, 2023 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that the first patient has been dosed in the Phase 1b/2a clinical trial of
Yahoo Finance: AnnJi Pharmaceutical Announced Licensing Agreement With Avenue Therapeutics To Develop And Commercialize AJ201, A First-In-Class Clinical Asset For The Kennedy’s Disease Treatment
TAIPEI, March 14, 2023 /PRNewswire/ — AnnJi Pharmaceutical Co. (AnnJi) has entered into an exclusive license agreement with Avenue Therapeutics Inc. (Avenue, NASDAQ: ATXI) for the development and commercialization of AJ201 in the U.S., Canada, European Union, Great Britain, and Israel for spinal and bulbar muscular atrophy (SBMA), also known as Kennedy’s Disease. Under the
Taiwan’s leading new drug developer in dermatology & neurology
Translation and development of new chemical entities from lead optimization, candidate selection to clinical proof-of-concept
